SG158068A1 - Polymorphs of sarsapogenin - Google Patents

Polymorphs of sarsapogenin

Info

Publication number
SG158068A1
SG158068A1 SG200907351-1A SG2009073511A SG158068A1 SG 158068 A1 SG158068 A1 SG 158068A1 SG 2009073511 A SG2009073511 A SG 2009073511A SG 158068 A1 SG158068 A1 SG 158068A1
Authority
SG
Singapore
Prior art keywords
sarsapogenin
polymorphs
sarsasapogenin
solvated
crystalline
Prior art date
Application number
SG200907351-1A
Other languages
English (en)
Inventor
Peter David Tiffin
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of SG158068A1 publication Critical patent/SG158068A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
SG200907351-1A 2004-11-05 2005-11-04 Polymorphs of sarsapogenin SG158068A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0424528A GB0424528D0 (en) 2004-11-05 2004-11-05 Chemical compounds

Publications (1)

Publication Number Publication Date
SG158068A1 true SG158068A1 (en) 2010-01-29

Family

ID=33523268

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907351-1A SG158068A1 (en) 2004-11-05 2005-11-04 Polymorphs of sarsapogenin

Country Status (17)

Country Link
US (1) US20080194530A1 (ja)
EP (2) EP2479183A3 (ja)
JP (1) JP2008519020A (ja)
KR (1) KR20070089798A (ja)
CN (2) CN102219826A (ja)
AU (1) AU2005300348A1 (ja)
BR (1) BRPI0517648A (ja)
CA (1) CA2584676A1 (ja)
GB (1) GB0424528D0 (ja)
IL (1) IL182879A0 (ja)
MX (1) MX2007005473A (ja)
NO (1) NO20072794L (ja)
RU (1) RU2007119611A (ja)
SG (1) SG158068A1 (ja)
TW (1) TW200635941A (ja)
WO (1) WO2006048665A2 (ja)
ZA (1) ZA200703630B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2389182A1 (en) 2009-01-24 2011-11-30 Phytopharm PLC Treatment of neurotrophic factor mediated disorders
AU2011281336B2 (en) 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
JP5881525B2 (ja) * 2011-05-16 2016-03-09 ライオン株式会社 サポゲニン安定化組成物の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
US2408827A (en) * 1944-05-15 1946-10-08 Parke Davis & Co Steroidal compounds and methods for obtaining the same
US2774714A (en) * 1952-10-10 1956-12-18 Emanuel B Hershberg Process for the extraction of sapogenins from plant materials
US3019220A (en) * 1958-07-17 1962-01-30 Julian Lab Inc Isolation of sapogenins
US4057543A (en) * 1976-07-01 1977-11-08 G. D. Searle & Co. Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
KR100217996B1 (ko) * 1996-12-23 1999-09-01 윤종용 프린트 헤드의 노즐 간격 보상 장치 및 방법
NZ507355A (en) 1998-03-26 2004-02-27 Phytopharm Plc Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
AT409100B (de) 2000-07-24 2002-05-27 Evg Entwicklung Verwert Ges Vorrichtung zum schweissen einer drahtgittermatte
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
KR20100093621A (ko) 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도

Also Published As

Publication number Publication date
TW200635941A (en) 2006-10-16
EP2479183A3 (en) 2013-08-28
CN101068827A (zh) 2007-11-07
CN102219826A (zh) 2011-10-19
CN101068827B (zh) 2011-06-08
NO20072794L (no) 2007-07-31
WO2006048665A3 (en) 2006-09-08
IL182879A0 (en) 2007-08-19
CA2584676A1 (en) 2006-05-11
AU2005300348A1 (en) 2006-05-11
BRPI0517648A (pt) 2008-10-14
RU2007119611A (ru) 2008-12-10
EP1809650A2 (en) 2007-07-25
MX2007005473A (es) 2007-05-24
EP2479183A2 (en) 2012-07-25
WO2006048665A2 (en) 2006-05-11
KR20070089798A (ko) 2007-09-03
US20080194530A1 (en) 2008-08-14
ZA200703630B (en) 2009-10-28
JP2008519020A (ja) 2008-06-05
GB0424528D0 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
AP2327A (en) Quinoline derivatives for the treatment of latent tuberculosis.
EP1948852A4 (en) REFERENCE ELECTRODE AND METHOD FOR PRODUCING THE REFERENCE ELECTRODE
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
HK1100409A1 (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
PT1928840E (pt) 1h-pirazole-4-carboxamidas, a sua preparação e a sua utilização a título de inibidores de 11-betahidroxiesteróide desidrogenase
PL1922309T3 (pl) Pochodne n-fenylo-2-pirymidynoaminy oraz sposób ich otrzymywania
NL1031845A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
EP1951681A4 (en) NEW 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE
EP1720893A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF ARTHRITIS
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
SG158068A1 (en) Polymorphs of sarsapogenin
GB0417803D0 (en) Algorithmic trading
SG155165A1 (en) Crystalline and amorphous forms of smilagenin
IL182951A0 (en) Enhancer of the effect of adrenocorticoid, comprising gum arabic
GB0516529D0 (en) Double stud fitting
WO2008021518A3 (en) Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride
WO2003099783A3 (en) Tropane compounds
AU2006315663A8 (en) KIFS as modifiers of the RHO pathway and methods of use